Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16
Open 57.18
Bid (Size) 56.74 (500)
Ask (Size) 58.29 (500)
Prev. Close 57.18
Today's Range 57.18 - 57.18
52wk Range 50.76 - 73.51
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy

Performance

YTD
-3.8%
-3.8%
1 Month
-6.5%
-6.5%
3 Month
+4.8%
+4.8%
6 Month
-4.3%
-4.3%
1 Year
-7.8%
-7.8%

More News

Read More
News headline image
10 Magnificent Stocks That Can Make You Richer in 2026 ↗
Via The Motley Fool
Topics Economy Stocks World Trade
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗
Via Chartmill
Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗
Via Stocktwits
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
Via StockStory
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Via StockStory
Topics Economy
News headline image
Which stocks are gapping on Friday? ↗
Via Chartmill
News headline image
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
Via StockStory
News headline image
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
2 Reasons to Like BMRN and 1 to Stay Skeptical
Via StockStory
Topics Stocks
News headline image
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy Government World Trade
News headline image
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
Via StockStory
News headline image
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 57.18
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 01/22/26 04:00 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.48B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.